Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Jo Howard, MBBChir, MRCP, FRCPath, Kenneth I. Ataga, MD, R. Clark Brown, MD PhD, Maureen Achebe, MD MPH, Videlis Nduba, MD, Amal El-Beshlawy, MD, Hoda Hassab, MD, Irene Agodoa, MD, Margaret Tonda, PharmD, Sarah Gray, PhD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Elliott Vichinsky, MD

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-140553

Published: 2020

Journal Articles

Correlation of Voxelotor Exposure with Hemoglobin Response and Measures of Hemolysis in Patients from the HOPE Study

Jo Howard, MB, BChir, Elliott Vichinsky, MD UCSF, Jennifer Knight-Madden, MBBS, PhD, Margaret Tonda, PharmD, Carla Washington, Barbara Tong, PhD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Victor R Gordeuk, MD

Blood (2019) 134 (Supplement_1): 1020.

https://doi.org/10.1182/blood-2019-130802

Published: 2019

Journal Articles

Improvement in Red Blood Cell Physiology in Children with Sickle Cell Anemia Receiving Voxelotor

Satheesh Chonat, MD, Earl Fields, Hannah Baratz, Amanda Watt, Mira Pochron, PhD, Sandy Dixon, Margaret Tonda, PharmD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Clark Brown, MD PhD, David R. Archer, PhD

Blood (2019) 134 (Supplement_1): 2281.

https://doi.org/10.1182/blood-2019-129351

Published: 2019

Journal Articles

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

Elliott P. Vichinsky, MD, Paul Telfer, DM, FRCP, Adlette Inati, MD, Margaret Tonda, PharmD, Barbara Tong, PhD, Irene Agodoa, MD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Kenneth I. Ataga, MD

Blood (2019) 134 (Supplement_1): 2313.

https://doi.org/10.1182/blood-2019-129026

Published: 2019

Journal Articles

Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study

Russell E. Ware, MD PhD, Clark Brown, MD PhD, Mariane de Montalembert, MD PhD, Margaret Tonda, PharmD, Barbara Tong, PhD, Carolyn Hoppe, MD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Miguel R. Abboud, MD

Blood (2019) 134 (Supplement_1): 1003.

https://doi.org/10.1182/blood-2019-130767

Published: 2019

NARROW

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Correlation of Voxelotor Exposure with Hemoglobin Response and Measures of Hemolysis in Patients from the HOPE Study

Improvement in Red Blood Cell Physiology in Children with Sickle Cell Anemia Receiving Voxelotor

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study

Email alerts

ASH Publications

American Society of Hematology

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Correlation of Voxelotor Exposure with Hemoglobin Response and Measures of Hemolysis in Patients from the HOPE Study

Improvement in Red Blood Cell Physiology in Children with Sickle Cell Anemia Receiving Voxelotor

Incidence of Vaso-Occlusive Crisis Does Not Increase with Achieving Higher Hemoglobin Levels on Voxelotor Treatment or after Discontinuation: Analyses of the HOPE Study

Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only